Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Deucravacitinib (BMS-986165) 是一种高选择性、口服生物可利用的变构 TYK2 抑制剂,用于治疗自身免疫性疾病。它通过稳定调节 JH2 结构域来阻断受体介导的 Tyk2 激活,可抑制IL-12/23和 I 型IFN 途径。它选择性结合 TYK2 假激酶 (JH2) 结构域,IC50为1.0 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 638 | 现货 | ||
5 mg | ¥ 1,570 | 现货 | ||
10 mg | ¥ 2,860 | 现货 | ||
25 mg | ¥ 4,570 | 现货 | ||
50 mg | ¥ 6,770 | 现货 | ||
100 mg | ¥ 9,180 | 现货 | ||
200 mg | ¥ 12,300 | 现货 | ||
500 mg | ¥ 18,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,730 | 现货 |
产品描述 | Deucravacitinib (BMS-986165) inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases. Which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. |
靶点活性 | JAK1 JH2:1 nM, TYK2 JH1:0.2 nM |
体外活性 | BMS-986165 maintains excellent potency in human and mouse whole blood (IC50s=13 and 100 nM, respectively). Which shows no significant hERG inhibition in the flux assay (IC50>80 μM).BMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism[1]. |
体内活性 | BMS-986165 as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2. In addition to unprecedented JAK isoform and kinome selectivity, BMS-986165 shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease. On the basis of these findings, BMS-986165 appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune diseases[1]. |
别名 | BMS-986165 |
分子量 | 425.46 |
分子式 | C20H19D3N8O3 |
CAS No. | 1609392-27-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32.5 mg/mL (76.39 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3504 mL | 11.752 mL | 23.504 mL | 58.7599 mL |
5 mM | 0.4701 mL | 2.3504 mL | 4.7008 mL | 11.752 mL | |
10 mM | 0.235 mL | 1.1752 mL | 2.3504 mL | 5.876 mL | |
20 mM | 0.1175 mL | 0.5876 mL | 1.1752 mL | 2.938 mL | |
50 mM | 0.047 mL | 0.235 mL | 0.4701 mL | 1.1752 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Deucravacitinib 1609392-27-9 Angiogenesis Chromatin/Epigenetic Immunology/Inflammation JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors Tyrosine Kinases JAK IFNAR Interleukin Janus kinase inhibit Interleukin Related Interferon-alpha/beta receptor Interferon-α/β receptor Inhibitor BMS 986165 BMS986165 BMS-986165 inhibitor